372 related articles for article (PubMed ID: 27151271)
1. Different clinical prognostic factors are associated with improved glycaemic control: findings from MARCH randomized trial.
Han J; Yu H; Tu Y; Pang J; Liu F; Bao Y; Yang W; Jia W
Diabet Med; 2017 Apr; 34(4):490-499. PubMed ID: 27151271
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of acarbose and metformin in newly diagnosed type 2 diabetes patients stratified by HbA1c levels.
Zhang JP; Wang N; Xing XY; Yang ZJ; Wang X; Yang WY
J Diabetes; 2016 Jul; 8(4):559-67. PubMed ID: 26331290
[TBL] [Abstract][Full Text] [Related]
3. Factors that influence the efficacy of acarbose and metformin as initial therapy in Chinese patients with newly diagnosed type 2 diabetes: a subanalysis of the MARCH trial.
Zhang J; Wang N; Xing X; Yang Z; Wang X; Yang W
Curr Med Res Opin; 2016; 32(4):713-9. PubMed ID: 26714411
[TBL] [Abstract][Full Text] [Related]
4. Acarbose compared with metformin as initial therapy in patients with newly diagnosed type 2 diabetes: an open-label, non-inferiority randomised trial.
Yang W; Liu J; Shan Z; Tian H; Zhou Z; Ji Q; Weng J; Jia W; Lu J; Liu J; Xu Y; Yang Z; Chen W
Lancet Diabetes Endocrinol; 2014 Jan; 2(1):46-55. PubMed ID: 24622668
[TBL] [Abstract][Full Text] [Related]
5. Glycemic excursions are positively associated with HbA1c reduction from baseline after treatment with acarbose in patients with type 2 diabetes on metformin monotherapy.
Wang JS; Lee IT; Lee WJ; Lin SD; Su SL; Tu ST; Tseng YH; Lin SY; Sheu WH
J Diabetes; 2017 Mar; 9(3):248-255. PubMed ID: 27043224
[TBL] [Abstract][Full Text] [Related]
6. Comparison of therapeutic effects of acarbose and metformin under different β-cell function status in Chinese patients with type 2 diabetes.
Fu J; Liu J; Xu Y; Yang N; Yang W; Wang G
Endocr J; 2019 May; 66(5):443-450. PubMed ID: 30944269
[TBL] [Abstract][Full Text] [Related]
7. Comparison of acarbose and metformin therapy in newly diagnosed type 2 diabetic patients with overweight and/or obesity.
Sun W; Zeng C; Liao L; Chen J; Wang Y
Curr Med Res Opin; 2016 Aug; 32(8):1389-96. PubMed ID: 27052634
[TBL] [Abstract][Full Text] [Related]
8. Retrospective comparison of voglibose or acarbose as an add-on therapy to sulfonylureas in Western Indian patients with uncontrolled overweight/obese type 2 diabetes.
Talaviya PA; Saboo BD; Dodiya HG; Rao SK; Joshi SR; Modh VB; Ghadiya SV
Diabetes Metab Syndr; 2016; 10(2):88-91. PubMed ID: 26777258
[TBL] [Abstract][Full Text] [Related]
9. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.
Wang JS; Lin SD; Lee WJ; Su SL; Lee IT; Tu ST; Tseng YH; Lin SY; Sheu WH
Clin Ther; 2011 Dec; 33(12):1932-42. PubMed ID: 22078152
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of acarbose add-on therapy in the treatment of overweight patients with Type 2 diabetes inadequately controlled with metformin: a double-blind, placebo-controlled study.
Halimi S; Le Berre MA; Grangé V
Diabetes Res Clin Pract; 2000 Sep; 50(1):49-56. PubMed ID: 10936668
[TBL] [Abstract][Full Text] [Related]
11. Associations between changes in glucagon-like peptide-1 and bodyweight reduction in patients receiving acarbose or metformin treatment.
Wang N; Zhang JP; Xing XY; Yang ZJ; Zhang B; Wang X; Yang WY
J Diabetes; 2017 Aug; 9(8):728-737. PubMed ID: 27717194
[TBL] [Abstract][Full Text] [Related]
12. Metformin or Acarbose Treatment Significantly Reduced Albuminuria in Patients with Newly Diagnosed Type 2 Diabetes Mellitus and Low-Grade Albuminuria.
Pan Q; Xu Y; Yang N; Gao X; Liu J; Yang W; Wang G
Med Sci Monit; 2018 Dec; 24():8941-8949. PubMed ID: 30531690
[TBL] [Abstract][Full Text] [Related]
13. Saxagliptin is similar in glycaemic variability more effective in metabolic control than acarbose in aged type 2 diabetes inadequately controlled with metformin.
Wang MM; Lin S; Chen YM; Shu J; Lu HY; Zhang YJ; Xie RY; Zeng LY; Mu PW
Diabetes Res Clin Pract; 2015 Jun; 108(3):e67-70. PubMed ID: 25841300
[TBL] [Abstract][Full Text] [Related]
14. Glipizide controlled-release tablets, with or without acarbose, improve glycaemic variability in newly diagnosed Type 2 diabetes.
Bao YQ; Zhou J; Zhou M; Cheng YJ; Lu W; Pan XP; Tang JL; Lu HJ; Jia WP
Clin Exp Pharmacol Physiol; 2010 May; 37(5-6):564-8. PubMed ID: 20082624
[TBL] [Abstract][Full Text] [Related]
15. A prospective, parallel group, open-labeled, comparative, multi-centric, active controlled study to evaluate the safety, tolerability and benefits of fixed dose combination of acarbose and metformin versus metformin alone in type 2 diabetes.
Jayaram S; Hariharan RS; Madhavan R; Periyandavar I; Samra SS
J Assoc Physicians India; 2010 Nov; 58():679-82, 687. PubMed ID: 21510461
[TBL] [Abstract][Full Text] [Related]
16. Secondary analysis of newly diagnosed type 2 diabetes subgroups and treatment responses in the MARCH cohort.
Wang W; Li X; Chen F; Wei R; Chen Z; Li J; Qiao J; Pan Q; Yang W; Guo L
Diabetes Metab Syndr; 2024 Jan; 18(1):102936. PubMed ID: 38171152
[TBL] [Abstract][Full Text] [Related]
17. MARCH2: comparative assessment of therapeutic effects of acarbose and metformin in newly diagnosed type 2 diabetes patients.
Wang G; Liu J; Yang N; Gao X; Fan H; Xu Y; Yang W
PLoS One; 2014; 9(8):e105698. PubMed ID: 25148570
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study.
Hoffmann J; Spengler M
Am J Med; 1997 Dec; 103(6):483-90. PubMed ID: 9428831
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomized, active comparator clinical trial.
Zang L; Liu Y; Geng J; Luo Y; Bian F; Lv X; Yang J; Liu J; Peng Y; Li Y; Sun Y; Bosch-Traberg H; Mu Y
Diabetes Obes Metab; 2016 Aug; 18(8):803-11. PubMed ID: 27060930
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of alogliptin versus acarbose in Chinese type 2 diabetes patients with high cardiovascular risk or coronary heart disease treated with aspirin and inadequately controlled with metformin monotherapy or drug-naive: A multicentre, randomized, open-label, prospective study (ACADEMIC).
Gao B; Gao W; Wan H; Xu F; Zhou R; Zhang X; Ji Q
Diabetes Obes Metab; 2022 Jun; 24(6):991-999. PubMed ID: 35112779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
